Editorial

Your role in establishing the real bioceconomy

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the European Commission on 13 February 2012, offers a unique approach to addressing these challenges in a comprehensive way.
In order to reduce heavy economic dependency on fossil resources and focus on mitigating climate change, Europe needs to move towards a post-petroleum society. The Bio­economy Strategy will contribute to this transition by promoting research and innovation into sustainable production and exploitation of renewable raw materials, along with alternative energy and carbon sources. It will pave the way to a more innovative and low-carbon society that reconciles food security with the sustainable use of renewable biological resources for industrial purposes, while simultaneously creating new job opportunities. Biotechnology as an enabling technology will play a crucial role in enhancing sustain­ability and competitiveness in the EU’s primary production and processing industries. It will also significantly contribute to reducing EU industry dependence on fossil resources, and improve the resource efficiency of production processes through the use of renewable raw materials (including wastes) and more environmentally-friendly bio-based processes.
The Bioeconomy Strategy is based on three complementary pillars. The first is aimed at increasing investment in research, innovation and skills. Under the European Framework “Horizon 2020” (2014-2020) Programme for Research and Innovation, €4.7bn of funding has been earmarked for bioeconomy research and innovation under the societal challenge “Food security, sustainable agriculture, marine and maritime research, and the bioeconomy” and for bio­technology as an enabling technology. It is estimated that this funding could generate about 130,000 new jobs and €45bn in value added in bioeconomy sectors by 2025, not taking into account other direct and indirect public and private investments into bioeconomy sectors. A Public Private Partnership for bio-based industries is under consideration.
The second pillar aims to improve synergies and coherence between priorities of European research and innovation policy and other policies relevant to the bioeconomy. It will provide different platforms to enhance interactions between researchers, policymakers, industries and society, as well as supporting similar initiatives in the EU Member States and Regions. The Strategy will also further develop international cooperation in the area of the bioeconomy.
In its third pillar, the Strategy provides support to new markets and the expansion of existing ones; for example, by promoting the develop­ment of standards, sustainability assessments and labels for bio-based products that will help facilitate their uptake in consumer markets and by green procurement. This promotes both the establishment of networks of integrated and diversified biorefineries, and demonstration and pilot plants across Europe. Finally, the Stra­tegy promotes the development of science-based approaches that can better inform consumers about product properties (like environmental sustainability) and aid in the promotion of a healthy and sustainable lifestyle.
Five Commissioners have demonstrated their strong commitment to the bioeconomy by co-signing the Bioeconomy Strategy. However, its success will very much depend on the commitment of member states, regions, stakeholders in the research and innovation community and citizens – like you.

Tech Review

06.03.2012

The Philogen group is a specialist for therapies against cancer. Unlike other private companies, the Swiss-Italian firm has developed a rich pipeline of antibodies consisting of five different molecules being tested in 15...

Tech Review

06.03.2012

Success in the biopharmaceutical industry is mainly driven by the ability to innovate, and the continuous development of new products is crucial in that context. Shortening development times is key. The use of comprehensive...

Tech Review

06.03.2012

Zurich-based NeurImmune AG follows unconventional routes – for example, the company doesn’t rely on VC investors. And Neurimmune has also turned the drug discovery process upside down by taking its drug candidates from healthy...

Tech Review

06.03.2012

The use of bispecific antibodies recognising two different targets may allow improvement of clinical efficacy. A bispecific antibody for two growth factors that stimulate the formation of blood vessels – Ang2 (Angiopoietin-2) and...

Clinical Trial

02.03.2012

Sweden’s Karo Bio AB has been hit hard by toxicity issues with its lead compound eprotirome. The anti-cholesterol drug – which was in Phase III clinical development – proved unsafe in a long-term animal tests. The drug lead to...

Clinical Trial

01.03.2012

Inspiration Biopharmaceuticals Inc. reported on 22 February that its lead candidate drug proved successful in a clinical trial involving 12 patients who suffer from hemophilia B. The results were presented at the 5th Annual EAHAD...

Politics / Law

24.02.2012

London – The European Medicines Agency (EMA) will publish information about all drugs under review, beginning on March 1. On a monthly basis the company will issue a list disclosing the international non-proprietary name and...

Displaying results 21 to 30 out of 1982

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/2/article/your-role-in-establishing-the-real-bioceconomy.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • MOLOGEN7.65 EUR18.42%
  • BB BIOTECH150.50 EUR5.10%
  • CO.DON2.69 EUR4.26%

FLOP

  • 4SC0.80 EUR-8.05%
  • CYTOS0.16 CHF-5.88%
  • WILEX2.15 EUR-4.44%

TOP

  • BIOFRONTERA2.85 EUR27.2%
  • MOLOGEN7.65 EUR3.4%
  • HBM85.50 CHF3.1%

FLOP

  • PAION2.20 EUR-32.3%
  • 4SC0.80 EUR-29.8%
  • CYTOS0.16 CHF-23.8%

TOP

  • SANTHERA81.90 CHF2267.1%
  • CO.DON2.69 EUR195.6%
  • PAION2.20 EUR155.8%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.80 EUR-54.0%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 21.10.2014


Current issue

All issues

Product of the week

Products